Video-on-Demand Library

This content is restricted to members of PSI. If you are already a member please login. To join PSI or to see all the benefits of membership click here.

26 January 2022

Kevin Ding and Juan Abellan

To assess the strength of clinical study findings regulatory authorities often request tipping point analyses to examine how extreme an assumption about imputed data would need to apply for conclusions to change. However what is a tipping point analysis, and how is one performed? What are the different approaches for continuous, binary and time to event data? Kevin Ding (AstraZeneca) and Juan Abellan (GlaxoSmithKline) present some practical examples.

Topic(s)

Upcoming Events

Latest Jobs